Chi-Med/AstraZeneca Partnership Starts Phase III Trial of c-MET Inhibitor

00:18 EDT 30 Jun 2017 | ChinaBio Today

Hutchison China MediTech (Chi-Med) and AstraZeneca announced the start of a global Phase III trial of their partnered drug, the c-MET inhibitor savolitinib. Savolitinib will be tested in c-MET driven papillary renal cell carcinoma. The trial's start triggers a $5 million milestone payment to Hutchison MediPharma, Chi-Med's novel drug company, according to the terms of the $140 million licensing agreement signed in 2011. The trial will be aimed at approval of savolitinib in the US and Europe. More details....

Stock Symbols: (AIM/NSDQ: HCM) (NYSE: AZN)

Share this with colleagues:  

Original Article: Chi-Med/AstraZeneca Partnership Starts Phase III Trial of c-MET Inhibitor


More From BioPortfolio on "Chi-Med/AstraZeneca Partnership Starts Phase III Trial of c-MET Inhibitor"

Quick Search


Relevant Topics

AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...